Insider sale details
LeonaBio, Inc. (NASDAQ:LONA) disclosed that President and Chief Executive Officer Mark James Litton sold 5,156 shares of common stock on March 4, 2026, according to a Form 4 filing with the Securities and Exchange Commission. The shares were sold at a weighted-average price of $5.37, producing proceeds of $27,687. Reported trade prices for the shares ranged from $5.03 to $5.70.
Option exercise and ownership stake
The filing also shows that on March 3, 2026, Litton exercised options on 22,254 shares of LeonaBio common stock with a transaction price of $0. Following the March 4 sale, Litton directly holds 57,926 shares of common stock. In addition to his direct holdings, he indirectly owns 656 shares each through Irrevocable Trusts of OSL, SWL and WGL, as indicated in the filing.
Stock performance and valuation context
The insider transactions take place while the stock has produced a 71% return over the past year. Public disclosures note that the share price has been highly volatile, with a reported beta of 2.76. Independent analysis referenced in company commentary indicates the stock currently appears overvalued relative to its Fair Value, based on InvestingPro analysis. The platform also notes that subscribers can access 13 additional InvestingPro Tips and detailed research through its Pro Research Report covering LONA and more than 1,400 other U.S. equities.
Corporate developments and strategic direction
LeonaBio has undergone a rebranding from Athira Pharma and completed a significant strategic shift by securing global rights - excluding Asia and certain Middle Eastern countries - to develop and commercialize lasofoxifene, a Phase 3 drug candidate for metastatic breast cancer. That transaction was supported by a $90 million upfront private placement and includes the potential for an additional $146 million in funding.
Analyst coverage has adjusted to reflect the company’s new focus. Mizuho upgraded LeonaBio’s rating from Neutral to Outperform, citing the potential of lasofoxifene as well as ATH-1105, which is positioned for Phase 2 trials targeting amyotrophic lateral sclerosis. Cantor Fitzgerald initiated coverage with an overweight rating. Separately, LeonaBio appointed Mark F. Kubik as Chief Business Officer to lead business development and corporate initiatives as the company focuses on advancing its cancer therapy portfolio.
Contextual note
The transactions and company updates outlined above are drawn from regulatory filings and company disclosures. The information on ownership, option exercises, the sale proceeds and price ranges reflects the entries on the Form 4 and related notices. The operational and financing details related to lasofoxifene, analyst ratings and the appointment of a new Chief Business Officer are part of the company’s public announcements.